# Chemical Safety Practices Recommendations

## Oxaliplatin (Eloxatin, [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II))

### Exposure Hazards (1, 2)

<table>
<thead>
<tr>
<th>Category 2 Warning</th>
<th>Category 2 Warning</th>
<th>Category 1 Warning</th>
<th>Category 1 Danger</th>
<th>Category 2 Warning Toxic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinogenicity</td>
<td>Germ Cell Mutagenicity</td>
<td>Skin Sensitization</td>
<td>Respiratory Sensitizer</td>
<td>Repeat/chronic exposure may damage gastro-intestinal tract, bone marrow, liver, kidneys, lungs, ears, and nervous system.</td>
</tr>
<tr>
<td>Suspected of Causing Cancer</td>
<td>Suspected of Causing Genetic Defects</td>
<td>May Cause An Allergic Skin Reaction</td>
<td>May Cause Allergy or Asthma if Inhaled.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category 2 Warning</th>
<th>Category 2A Warning</th>
<th>Category 3 Warning Toxic</th>
<th>Category 2 Warning</th>
<th>Category 3 Warning Toxic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin Irritation</td>
<td>Eye Irritation</td>
<td>Toxic If Swallowed</td>
<td>May Cause Respiratory Irritation</td>
<td>Suspected of Damaging Fertility or the Unborn Child</td>
</tr>
</tbody>
</table>

### Response to Exposure

<table>
<thead>
<tr>
<th>Oral</th>
<th>Dermal</th>
<th>Inhalation</th>
<th>Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinse mouth; do not induce vomiting. Report to OHS.</td>
<td>Wash skin with soap and water for 15 minutes. Rinse eyes for 15 minutes. Report to OHS.</td>
<td>Leave area; go to clean air. Report to OHS.</td>
<td>Report to OHS.</td>
</tr>
</tbody>
</table>

### Special Precautions

- Pregnant women should exercise caution when working with Oxaliplatin. (3)
- Discard garments as hazardous if contaminated with Oxaliplatin.

### Personal Protective Equipment

- Gloves (Double glove) (Latex or Nitrile)
- Skin Protection (Suit or Scrubs or Lab Coat)
- Eye Protection (Safety-glasses or Goggles)
- Closed-toe shoes
- Use N100 respirator if engineering controls are not available.

### Engineering Controls

- Oxaliplatin powder- Chemical Fume Hood (CFH) (4)
- Oxaliplatin solution- CFH or Biosafety Cabinet (Class II, B2 BSC if aerosolized)
- Animal waste and bedding until one day after last treatment- CFH or Class II, B2 BSC (5, 6)

### Animal Handling

- Avoid exposure to animal urine until one day after last treatment.

### Bedding Disposal

- Dispose of bedding as hazardous material until one day after last treatment.

### Work Practices

- Empty Oxaliplatin containers and unused Oxaliplatin must be disposed of as hazardous.
- Follow LASP SOPs for preparation, handling, dosing, and disposal of Oxaliplatin.

Questions or concerns: Please contact EHS, Ted Witte, theodore.witte@nih.gov or 301-846-5860
Reviewed 02/09/2015  These recommendations are not final and may be updated.
Oxaliplatin is used to treat colorectal cancer as part of the FOLFOX treatment regimen. It is a platinating anti-neoplastic drug similar to Carboplatin and Cisplatin, with excretion kinetics similar to those of Cisplatin. The drug is rapidly hydrolyzed in the blood serum to its active form and binds to proteins and DNA. The major route of excretion of oxaliplatin and its metabolites is through the urine. Free Oxaliplatin and toxic metabolites may be excreted for several hours after treatment.

Oxaliplatin should be handled with respect because it is a potent compound capable of causing allergic sensitization and potentially cancer and damage to the unborn child. However, the user should not be alarmed by the large number of warning pictograms included in this particular CSPR. Hazards are not listed unless there is sufficient information to believe that they apply, the lack of a hazard listing does not mean that the hazard may not possibly exist. In this instance, the hazards of the drug are very well studied and therefore the list is much more complete than in other CSPRs which have been issued.

References:

Questions or concerns: Please contact EHS, Ted Witte, theodore.witte@nih.gov or 301-846-5860
Reviewed 02/09/2015  These recommendations are not final and may be updated.